| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the Department of Medicine, University of Medicine and Dentistry of New Jersey New Jersey Medical School, Newark
Study objectives: To determine if treatment with low-dose methotrexate spares oral steroids in adult, steroid-dependent, asthmatic patients.
Design: Articles identified by computer search were excluded if they (1) did not contain original data relating to the primary question, (2) had no controls, or (3) described subjects younger than 18 years of age.
Measurements: From each article, the following was abstracted: reference citation; type of control; whether study incorporated a run-in period in which the baseline level of prednisone was reduced to the lowest possible dose; dosage and length of methotrexate therapy; baseline dosage; and type of steroid. Also, the following was determined during both placebo and methotrexate arms of each study: steroid dosage, FEV1, serious side effects, and alteration in level of serum aspartate aminotransferase.
Results: Eleven eligible studies were identified. Methotrexate treatment resulted in a decrease in prednisone or prednisolone usage by an average of 4.37 mg/d or 23.7% of the initial dosage. The summary effect size in standard deviations (SDs) was 
0.53 (95% confidence interval=0.29 to 0.77). Subgroup analysis showed that patients treated with prolonged (6-month) therapy with methotrexate, those with low long-term usage of steroids (
20 mg/d), and those whose study design incorporated a run-in period, tended to have the greatest steroid-sparing effects with methotrexate.
Conclusions: Low-dose methotrexate has a significant steroid-sparing effect in steroid-dependent asthmatic patients. The greatest effect was evident in patients in whom an effort was made to reduce baseline steroid dosage and in whom methotrexate was used for 24 weeks.
Key Words: asthma • prednisolone • prednisone • pulmonary function tests
Submitted on December 6, 1996
Accepted on January 29, 1997
This article has been cited by other articles:
|
|
 |
|
  E. M. Erin, B. R. Leaker, G. C. Nicholson, A. J. Tan, L. M. Green, H. Neighbour, A. S. Zacharasiewicz, J. Turner, E. S. Barnathan, O. M. Kon, et al. The Effects of a Monoclonal Antibody Directed against Tumor Necrosis Factor-{alpha} in Asthma Am. J. Respir. Crit. Care Med., October 1, 2006; 174(7): 753 - 762. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Strek Difficult asthma. Proceedings of the ATS, January 1, 2006; 3(1): 116 - 123. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Other drugs for severe asthma and unconventional therapies Can. Med. Assoc. J., November 1, 1999; 161(90111): s39 - 43. [Full Text]
|
|
|
|
 |
|
 I. Balfour-Lynn Difficult asthma: beyond the guidelines Arch. Dis. Child., February 1, 1999; 80(2): 201 - 206. [Full Text]
|
|
|
|
 |
|
 R. A. Robbins, P. A. Jinkins, T. W. Bryan, S. C. Prado, and S. A. Milligan Methotrexate Inhibition of Inducible Nitric Oxide Synthase in Murine Lung Epithelial Cells In Vitro Am. J. Respir. Cell Mol. Biol., June 1, 1998; 18(6): 853 - 859. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
